N/A N=32 Use of the FreeStyle Navigator Continuous Glucose Monitoring System to Enhance Education and Glycaemic Control
Diabetes Mellitus
Primary: Change in HbA1C From Baseline to 6 Months — 9.3; 9.1 HbA1c % — p=0.014
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=76 S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Survival at 1 Year — 93 percentage of patients
Phase 4 N=62 Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)
Congestive Heart Failure · Insulin Resistance
Primary: Peak VO2 — -0.38; 3.6 ml/kg/min — p=0.08
Phase 3 N=1,565 Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®
Pregnancy
Primary: The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy. — 0.12; 0.12 6 month probability of pregnancy
Phase 1 N=5 Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Conjunctival Neoplasms
Primary: Number of Patients Assessed for Safety and Tolerability — 5 participants
Phase 3 N=255 Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
Secondary Hyperparathyroidism · Hemodialysis
Primary: Percentage of Participants With Target Intact Parathyroid Hormone (iPTH) and Without Hypercalcemia — 27.7; 30.5 percentage of participants
Phase 3 N=347 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
N/A N=72 For the Health of Our Children--Clinic Based Treatment of Childhood Obesity
Obesity
Primary: Body Mass Index Z-score Change — -0.02; -0.08 BMI z-score change
N/A N=26 The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial
Pressure Ulcer
Primary: % Viable Tissue — 43.06; 25.94 Percentage of viable tissue — p=0.023
Phase 2 N=28 Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
Type 2 Diabetes · Insulin Resistance · Metabolic Syndrome
Primary: Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR) — 17.95; 1.68 micromols/kg of FFM/minute — p=<0.001
N/A N=100 Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF
Capsule Opacification · Pseudophakia · Cataract
Primary: Posterior Capsule Opacification (PCO) — 3.0; 1.9 units on a scale (0-10)
Phase 4 N=83 Lumbar Plexus Block for Postoperative Pain Control After Hip Arthroscopy. A Randomized Controlled Trial
Postoperative Pain
Primary: Numeric Rating Scale (NRS) Pain at Rest (0-10) on Day of Surgery Prior to Discharge — 3.3; 4.2 units on a scale
Phase 2 N=20 Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma
Asthma
Primary: Number of Asthma Exacerbations in Three Months — 30; 31 exacerbations
Phase 2 N=308 Late Phase 2 Study of OPC-12759 Ophthalmic Suspension
Dry Eye Syndromes
Primary: Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF) — -3.5; -3.7; -1.8 FCS score — p=0.001
Phase 4 N=133 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale